Strategic partnerships for life sciences innovation.
Syzent Partners LLC positions clinical and pre-IND stage life sciences companies to secure high-value strategic partnerships and advance novel products towards commercialization.
comes from the astronomical term syzygy, combined with transparent. Syzygy occurs when three objects are aligned within a planetary system, like an eclipse of the moon. Solid partnerships are based on aligning complex science, strategic considerations and the right alliance framework.
Our business philosophy is anchored on three principles: transparency, integrity and commitment to client goals.
(excluding university licenses)
proceeds and realized value
Managing Partner Michael Atkin has successfully executed 16 life sciences partnerships (excluding university licenses) and 4 consumer/industrial M&As. He has consistently steered multiple early-stage biotechnology firms through critical inflection points. Michael is an experienced partnership strategist and seasoned life sciences executive with a track record spanning over $2 billion in value generation, aggregate proceeds and realized value from executed mergers and acquisitions, corporate spin-offs, and therapeutic partnerships.
Bridging Strategy & Execution
Unlike advisors who operate from the sidelines, Michael brings hands-on CEO-level accountability to the deal table. His advisory approach is intensely operational:
-
01
Diligence-Readiness
Evaluating freedom to operate, identifying missing data gaps, and optimizing the Target Product Profile (TPP) alongside the scientific team and Key Opinion Leaders (KOLs) to withstand rigorous pharma scrutiny
-
02
Partnering Structure
Designing partnering approaches, executing valuation models, and writing definitive term sheets that protect long-term corporate value
-
03
Crisis & Conflict Resolution
Experience defusing partner volatility and settling international litigation enabling two product acquisitions; structured two complex merger agreements under high pressure
A Career Built on Partnership and Results
Michael learned business development and strategic marketing from Fortune 100 multinationals—including Bristol Myers Squibb (BMS), Lederle International (Wyeth/Pfizer) and Allied-Signal. He has steered numerous early-stage biotech firms through critical inflection points and partnerships as a serial CEO, Board Chair and mentor.
Let's align strategy with opportunity.
For clinical and pre-IND life sciences companies seeking the right strategic partnership.